BEYOND THE EXTRA CHROMOSOME: A MULTIDISCIPLINARY APPROACH TO UNDERSTANDING THE COMPLEXITIES OF DOWN SYNDROME AND ADVANCING THERAPEUTIC STRATEGIES

Abstract

Down syndrome, most frequently triggered by trisomy 21, remains one of complicated neurodevelopmental disorder, affecting development from the Prenatal stage through adulthood. While its heredity basis has been known for long periods, Down syndrome persists to be under-investigated in multiple physiological and clinical aspects. This review supplies a comprehensive, multi-omics analysis that moves beyond the standard chromosomal perspective awareness of the syndrome. By re-examining the historical trajectory of Down syndrome, from its early medical description to detection of trisomy 21, we emphasize how research progress has defined modern diagnostic and treatment strategies. Upcoming genomic and epigenetic evidence highlights that Down syndrome pathology is not only the result of an additional chromosome 21 but shows wider dosage alterations, disturbed regulatory network, and global epigenetic drift. These modifications impacted mitochondrial performance, immune monitoring, biochemical pathways, and neurodevelopment, leading to the condition’s wide phenotypic range. Specific alterations are given to mosaic and segmented trisomy types, which offers distinct possibilities to clarify genotype. Despite progress, significance gaps remain, including limited understanding of cortical formation, immune imbalance, nutritional factors and age associated risks. By gathering insights from genome wide analysis, protein profiling, metabolite analysis and clinical research, this review highlights how holistic biology can reframe the upcoming periods of Down syndrome. Ultimately, we argue for a unified multi-omics framework that can inform targeted diagnostic, early stage strategy and advanced, therapeutic approaches for individuals with Down syndrome